Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process 
Mastercard Explores Sale of Majority Stake in UK Payments Firm Vocalink: Report 
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors 
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings 
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand 
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target 
Genesis Minerals to Acquire Vault in A$5.6 Billion Deal After Regis Withdraws 
SK Hynix Soars 13% in Nasdaq Debut After Record $26.5 Billion IPO 
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth 
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand 
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing 
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside 
Apple Sues OpenAI, Former Employees Over Alleged Trade Secret Theft 
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI 
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO 
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion 
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business 
MENLO PARK, Calif., Nov. 30, 2015 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that John A. Scarlett, M.D., President and Chief Executive Officer, is scheduled to present at the following investor conferences:
- Piper Jaffray 27th Annual Healthcare Conference in New York at 8:30 a.m. ET on Wednesday, December 2, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/u46tsbd2.
- Oppenheimer 26th Annual Healthcare Conference in New York at 9:45 a.m. ET on December 9, 2015. The live and archived webcast will be available at http://www.veracast.com/webcasts/opco/healthcare2015/84203554236.cfm.
Geron management will also be hosting an analyst and investor meeting to discuss imetelstat data presented at the 57th American Society of Hematology (ASH) Annual Meeting:
- The meeting will be held at 7:30 p.m. ET on Saturday, December 5, 2015. The live and archived webcast will be available at http://edge.media-server.com/m/p/o3ovz2db/lan/en.
Following the live presentations, the webcasts will be archived and available for replay for a period of 30 days.
About Geron
Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.
CONTACT: Anna Krassowska, Ph.D. Investor and Media Relations 650-473-7765 [email protected] [email protected]
